References

Acute lymphoblastic leukemia in children

10.1056/nejmra1400972 · 2015 · External reference

Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial

10.1001/jama.2021.0669 · 2021 · External reference

Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial

10.1001/jama.2021.0987 · 2021 · External reference

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

10.1056/nejmoa1709866 · 2018 · External reference

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

10.1016/s0140-6736(14)61403-3 · 2015 · External reference

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

10.1182/blood-2017-02-769208 · 2017 · External reference

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

10.1182/blood-2014-12-580068 · 2015 · External reference

Engineered T cells: the promise and challenges of cancer immunotherapy

10.1038/nrc.2016.97 · 2016 · External reference

Unresolved reference

2025 · External reference

Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results

10.1200/jco.2024.42.16_suppl.10016 · 2024 · External reference

A comparison of chimeric antigen receptors containing CD28 versus 4–1BB costimulatory domains

10.1038/s41571-021-00530-z · 2021 · External reference

Chimeric antigen receptor T cell therapy in childhood leukaemia

10.1136/archdischild-2024-328263 · 2025 · External reference

Foundation for the Accreditation of Cellular Therapy

External reference

INSPIRED symposium part 2: prevention and management of relapse following chimeric antigen receptor T cell therapy for B cell acute lymphoblastic leukemia

10.1016/j.jtct.2023.08.030 · 2023 · External reference

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

10.1038/s41571-022-00607-3 · 2022 · External reference

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy

10.1016/j.it.2004.12.003 · 2005 · External reference

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

10.1038/s41571-018-0075-2 · 2019 · External reference

Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

10.3389/fimmu.2023.1303935 · 2023 · External reference

The current state of chimeric antigen receptor T cell therapy for B lymphoblastic leukemia

10.1016/j.hoc.2023.06.003 · 2023 · External reference

Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy

10.1016/j.jtct.2023.11.008 · 2024 · External reference

Chimeric antigen receptor T cells for sustained remissions in leukemia

10.1056/nejmoa1407222 · 2014 · External reference

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

10.1038/s41591-019-0549-5 · 2019 · External reference

Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis

10.1001/jamaoncol.2017.0580 · 2017 · External reference

Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia

10.1200/jco.22.01076 · 2023 · External reference

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

10.1182/bloodadvances.2020003092 · 2020 · External reference

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

10.1182/blood.2021012727 · 2022 · External reference

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

10.1016/s2352-3026(21)00238-6 · 2021 · External reference

National Comprehensive Cancer Network

External reference

Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia

10.1158/2643-3230.bcd-21-0095 · 2022 · External reference

Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

10.1200/jco.22.00642 · 2023 · External reference

Mechanisms of resistance to CAR T cell therapy

2019 · External reference

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany

10.1182/bloodadvances.2022008981 · 2023 · External reference

Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia

10.1200/jco.20.03458 · 2021 · External reference

Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children

10.1056/nejmoa2411680 · 2025 · External reference

Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia

10.1097/moh.0000000000000685 · 2021 · External reference

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

10.1200/jco.20.02262 · 2021 · External reference

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

10.1016/j.bbmt.2018.12.758 · 2019 · External reference

How I treat cytopenias after CAR T-cell therapy

2023 · External reference

Chimeric antigen receptor t cell therapy for pediatric B-ALL: narrowing the gap between early and long-term outcomes

10.3389/fimmu.2020.01985 · 2020 · External reference

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults

10.1182/bloodadvances.2024013243 · 2024 · External reference

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy

10.1111/tid.14109 · 2023 · External reference

Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia

10.1001/jamapediatrics.2018.2530 · 2018 · External reference

Estimation of total costs in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia receiving tisagenlecleucel from a U.S. hospital’s perspective

2020 · External reference

CAR T cells and T-cell therapies for cancer: a translational science Review

10.1001/jama.2024.19462 · 2024 · External reference

Assessing Medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T cell therapy: a project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative

10.1016/j.jtct.2023.08.007 · 2023 · External reference

Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia

10.1093/jnci/djy193 · 2019 · External reference

A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults

10.1016/j.jcyt.2023.05.011 · 2023 · External reference

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma

10.1182/bloodadvances.2024013586 · 2025 · External reference

Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium

10.1016/j.jtct.2023.07.009 · 2023 · External reference

Engineering in vivo CAR-T cells

10.1038/s41591-026-04296-8 · 2026 · External reference

CAR-T cell therapy embarks on autoimmune disease

10.1038/s41409-024-02429-6 · 2025 · External reference